Sarepta Therapeutics Says Patient Dies After Elevidys Gene Therapy for Duchenne Muscular Dystrophy; Shares Fall

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Sarepta Therapeutics Says Patient Dies After Elevidys Gene Therapy for Duchenne Muscular Dystrophy; Shares Fall

, MT Newswires - 2:37 PM ET 3/18/2025 Company News

02:37 PM EDT, 03/18/2025 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) shares were down nearly 23% in recent Tuesday trading after the biopharmaceutical company said a young patient with Duchenne muscular dystrophy passed away due to acute liver failure following treatment with its Elevidys gene therapy.

Acute liver injury, including failure, is a known side effect of Elevidys and other adeno-associated viruses-based gene therapies, though this level of severity was not previously reported, the company said.

The patient had a recent cytomegalovirus infection, which may have contributed to the liver damage, Sarepta Therapeutics ( SRPT ) said.

The company said it is continuing its investigation into the incident, has informed health authorities, and will update the prescribing information.

Price: 76.80, Change: -24.55, Percent Change: -24.22

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.